Q-omics provides the consensus-scored MIR1255B2 profile across patient tissues and cancer cell-line models. MIR1255B2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR1255B2 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR1255B2 RNA expression shows 6,558 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, STAD, and UCEC as cancer lineages where MIR1255B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1255B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1255B2 survival associations across molecular data types. MIR1255B2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1255B2 RNA expression–survival associations across cancer types. High MIR1255B2 expression shows unfavorable associations in ACC, ESCA, MESO and BLCA, but favorable associations in HNSC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR1255B2 RNA expression.
This table summarizes MIR1255B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1255B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1255B2 shows lower tumor expression in THCA and higher tumor expression in STAD. The STAD box plot shows higher MIR1255B2 RNA expression in tumor versus normal tissue (log2 FC = +0.208, t-test p = .024).
This table shows molecular features associated with MIR1255B2 in patient tissues and cancer cell lines. In patient samples, MIR1255B2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
